Cargando…
PB2000: LESSONS LEARNED FROM CERBA RESEARCH CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR T) MULTIPLE MYELOMA RUNNING TRIALS
Autores principales: | Gaspo, R., Selliah, N., Clottens, F., Modi, I., Sallette, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429149/ http://dx.doi.org/10.1097/01.HS9.0000850832.20806.45 |
Ejemplares similares
-
PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS
por: Gaspo, Rania, et al.
Publicado: (2023) -
PB1999: ATG-010 PLUS LOW-DOSE DEXAMETHASONE (SD) IN CHINESE RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS PREVIOUSLY RECEIVED CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T)
por: Fu, W., et al.
Publicado: (2022) -
PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Mohammed, Turab, et al.
Publicado: (2023) -
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA
por: Accorsi Buttini, E., et al.
Publicado: (2022) -
PB1983: TRIAL-IN-PROGRESS: PHASE II STUDY OF PHE885, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
por: Munshi, N., et al.
Publicado: (2022)